Patton Fund Management Inc. trimmed its holdings in DaVita Inc. (NYSE:DVA - Free Report) by 22.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,348 shares of the company's stock after selling 6,336 shares during the period. Patton Fund Management Inc.'s holdings in DaVita were worth $3,266,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently made changes to their positions in the company. Invesco Ltd. grew its holdings in DaVita by 20.9% during the 4th quarter. Invesco Ltd. now owns 1,589,545 shares of the company's stock valued at $237,716,000 after buying an additional 275,284 shares in the last quarter. Northern Trust Corp boosted its position in shares of DaVita by 12.5% during the fourth quarter. Northern Trust Corp now owns 740,774 shares of the company's stock worth $110,783,000 after acquiring an additional 82,326 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in DaVita by 14.0% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 466,046 shares of the company's stock valued at $69,697,000 after acquiring an additional 57,386 shares in the last quarter. Amundi lifted its stake in DaVita by 116.4% in the 4th quarter. Amundi now owns 446,386 shares of the company's stock worth $68,726,000 after purchasing an additional 240,126 shares in the last quarter. Finally, Deutsche Bank AG boosted its holdings in shares of DaVita by 35.2% during the 4th quarter. Deutsche Bank AG now owns 392,422 shares of the company's stock valued at $58,687,000 after purchasing an additional 102,230 shares during the last quarter. Institutional investors own 90.12% of the company's stock.
DaVita Trading Down 0.6%
NYSE DVA traded down $0.86 on Wednesday, hitting $135.65. 833,544 shares of the stock were exchanged, compared to its average volume of 821,547. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.20 and a current ratio of 1.25. DaVita Inc. has a 52-week low of $131.76 and a 52-week high of $179.60. The firm has a market capitalization of $10.24 billion, a P/E ratio of 13.44, a P/E/G ratio of 0.94 and a beta of 1.11. The stock has a fifty day moving average price of $140.57 and a two-hundred day moving average price of $150.58.
DaVita (NYSE:DVA - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The company reported $2.00 EPS for the quarter, topping analysts' consensus estimates of $1.75 by $0.25. The firm had revenue of $3.22 billion during the quarter, compared to analysts' expectations of $3.22 billion. DaVita had a net margin of 6.63% and a return on equity of 176.11%. The firm's revenue for the quarter was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company earned $2.26 EPS. Research analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities analysts recently commented on the company. Sanford C. Bernstein set a $184.00 price target on DaVita in a research note on Friday, February 21st. Wall Street Zen upgraded DaVita from a "hold" rating to a "buy" rating in a research report on Friday, April 25th. Cowen reissued a "hold" rating on shares of DaVita in a report on Tuesday, February 18th. Barclays upped their price target on shares of DaVita from $164.00 to $169.00 and gave the company an "equal weight" rating in a research note on Tuesday, February 18th. Finally, Truist Financial reduced their target price on shares of DaVita from $170.00 to $164.00 and set a "hold" rating on the stock in a report on Monday, May 19th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $164.50.
Read Our Latest Stock Report on DaVita
DaVita Profile
(
Free Report)
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
